HEPATIC FORMATION AND HANDLING OF DRUG METABOLITES
HEPATIC FORMATION AND HANDLING OF DRUG METABOLITES
批准号:
3294487
负责人:
KIM-CHING S PANG
金额:
$14.91万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1987
资助国家:
美国
项目状态:
已结题
起止时间:
1987-04-01 至 1990-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
We wish to test the hypothesis that hepatic formation of
metabolites occurs as a distributed-in-space phenomenon: the
sojourns of a locally generated metabolite will differ from that of
preformed metabolite due to their differing points of entry into
the liver. These differences occur because input as generated
metabolite depends on drug uptake and metabolism, and formation
of any metabolite from a precursor must precede metabolite
elimination. The elimination of metabolite generated from
precursor and preformed metabolite will differ despite
involvement of the same metabolizing enzyme(s) and processes
for transfer across cells. We propose to develop an indepth
theoretical treatment of a drug that forms a) a single metabolite
which in turn is not further eliminated (metabolized or excreted),
b) a single metabolite which is further eliminated, and c) two or
more metabolites formed by competing pathways.
Experimentally, we wish to study the following substrates and
their metabolites in the perfused rat liver preparation: a) 3H-
acetaminophen (A) and 3H-salicylamide and their 35S-sulfate
conjugates; b) 14C-enalapril and 3H-enalaprilat; 3H-morphine and
14C-morphine glucuronide; 14C-acetanilide and its p-alkoxy
analogs to 14C-A and 14C-AS; c) 3H-harmol and 3H-4-
methylumbelliferone and their labeled (35S)-sulfates and (14C)-
glucuronides (in absence and presence of sulfate inhibitor, DCNP),
compounds that will be assayed by TCL and HPLC. While
maintaining a single pass liver perfusion with steadystate
infusions of unlabeled drug or preformed metabolite (varying
levels of input concentrations), a rapid injection of radiolabeled
drug and metabolite and vascular reference compounds (51Cr-
RBC, 125I-albumin, and 32p-phosphate) will be used to produce a
set of multiple indicator dilution curves (MID). The various
techniques (normal, retrograde, hepatic artery) of oncethrough
perfusion and MID will provide information on underlying
processes: red cell and protein binding, influx (barrier-limited,
flowlimited, and carrier- or concentrative mechanisms), efflux,
and sequestration of drug and metabolite formation as well as the
behaviour of preformed metabolite under both linear and
nonlinear conditions. The theoretical development and the
experimentally-acquired information will further our knowledge
on the differences in hepatic handling between a generated vs
preformed metabolite, and provide a solid basis for understanding
the toxicological/pharmacological differences in generation and
processing of drug metabolites.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
HEPATIC FORMATION AND HANDLING OF DRUG METABOLITES
-
批准号:2179232
-
项目类别:
-
资助金额:$15.55万
-
财政年份:1991
-
负责人:KIM-CHING S PANG
-
依托单位:
HEPATIC FORMATION AND HANDLING OF DRUG METABOLITES
-
批准号:2179234
-
项目类别:
-
资助金额:$17.39万
-
财政年份:1991
-
负责人:KIM-CHING S PANG
-
依托单位:
HEPATIC FORMATION AND HANDLING OF DRUG METABOLITES
-
批准号:2331964
-
项目类别:
-
资助金额:$18.24万
-
财政年份:1991
-
负责人:KIM-CHING S PANG
-
依托单位:
HEPATIC FORMATION AND HANDLING OF DRUG METABOLITES
-
批准号:3294484
-
项目类别:
-
资助金额:$14.38万
-
财政年份:1991
-
负责人:KIM-CHING S PANG
-
依托单位:
HEPATIC FORMATION AND HANDLING OF DRUG METABOLITES
-
批准号:2179235
-
项目类别:
-
资助金额:$17.55万
-
财政年份:1991
-
负责人:KIM-CHING S PANG
-
依托单位:
HEPATIC FORMATION AND HANDLING OF DRUG METABOLITES
-
批准号:3294489
-
项目类别:
-
资助金额:$16.55万
-
财政年份:1991
-
负责人:KIM-CHING S PANG
-
依托单位:
HEPATIC FORMATION AND HANDLING OF DRUG METABOLITES
-
批准号:3294488
-
项目类别:
-
资助金额:$14.02万
-
财政年份:1987
-
负责人:KIM-CHING S PANG
-
依托单位:
HEPATIC FORMATION AND HANDLING OF DRUG METABOLITES
-
批准号:3294483
-
项目类别:
-
资助金额:$15.35万
-
财政年份:1987
-
负责人:KIM-CHING S PANG
-
依托单位:
海外基金